Journal of Pharmaceutical Investigation
- 제31권2호
- /
- Pages.125-130
- /
- 2001
- /
- 2093-5552(pISSN)
- /
- 2093-6214(eISSN)
리마틸 정(부시라민 100 mg)에 대한 부시린 정의 생물학적 동등성
Bioequivalence of Bucilin Tablet to Rimatil Tablet (Bucillamine 100 mg)
- 조혜영 (전남대학교 약학대학/약품개발연구소) ;
- 이문석 (전남대학교 약학대학/약품개발연구소) ;
- 오인준 (전남대학교 약학대학/약품개발연구소) ;
- 김동현 (한국과학기술연구원) ;
- 문재동 (전남대학교 의과대학) ;
- 이용복 (전남대학교 약학대학/약품개발연구소)
- Cho, Hea-Young (College of Pharmacy and Research Institute of Drug Development, Chonnam National University) ;
- Lee, Moon-Seok (College of Pharmacy and Research Institute of Drug Development, Chonnam National University) ;
- Oh, In-Joon (College of Pharmacy and Research Institute of Drug Development, Chonnam National University) ;
- Kim, Dong-Hyun (Korea Institute of Science and Technology) ;
- Moon, Jai-Dong (Medical School, Chonnam National University) ;
- Lee, Yong-Bok (College of Pharmacy and Research Institute of Drug Development, Chonnam National University)
- 발행 : 2001.06.20
초록
Bucillamine is a novel cysteine derivative with two free intramolecular sulfhydryl groups, and has a preventive and therapeutic effect on adjuvant arthritis, suggesting its antirheumatic action. With respect to the effect on the immune system, bucillamine-exerted such immunoregulating actions are to nomalize an excessive reduction or acceleration in immune reaction. It is useful not only in patients with early stage of rheumatoid arthritis (RA) but also in those with active RA retained for more than 10 years. The purpose of the present study was to evaluate the bioequivalence of two bucillamine tablets,